((自动化翻译由路透提供，请见免责声明 ))
9月25日 - ** 癌症疗法制造商2seventy bio 股价盘前下跌9.8%至4.30美元
** 该公司及其合作伙伴百时美施贵宝 将停止其细胞疗法在新诊断的多发性骨髓瘤患者中的晚期试验 (link)。
** 多发性骨髓瘤是一种影响骨髓浆细胞的血癌
** 做出这一决定是因为符合试验条件的患者人数大大少于最初设计该研究时的人数
** TSVT 将在未来几年节省 8000 多万美元，并有助于在 2025 年提前实现收支平衡
** BMY和TSVT将与研究人员合作，为目前入组的患者确定适当的下一步治疗方案
** 截至上一交易日收盘，TSVT 股价年累计上涨 11
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.